HENLIUS (02696.HK) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Quote List Quote List

Event Tracking

Dec30

Fosun Henlius' Three New Drugs Clinical Trial Applications Accepted by NMPA

10:41

Dec29

Fosun Huayi Biotechnology Launches HLX37 Clinical Trials for Advanced Solid Tumors

10:31

Fulink Hanlin completes first patient dosing for HLX37

09:57

Dec23

Dr. Zhu Jie, CEO of Henlius, to speak at the 44th J.P. Morgan Healthcare Conference

13:54

Dec19

Fosun Pharma and Subsidiary Fosun Henlius Obtain FDA Approval

11:32

F.H. ChinaBio Secures FDA Approval for HLX18 Biosimilar Phase I Clinical Trial

09:04

Schedules & Filings

Schedules

Filings

Aug25

Earning Release(CST)

FY2025 Q2 Earning Release (HKD) Revenue 1.543 B, Net Income 213.5 M, EPS 0.3928

Mar24

Earning Release(CST)

FY2024 Q4 Earning Release (HKD) Revenue 1.584 B, Net Income 230.95 M, EPS 0.4249

Aug26

Earning Release(CST)

FY2024 Q2 Earning Release (HKD) Revenue 1.475 B, Net Income 207.55 M, EPS 0.3814

Stock List

Top Gainers

Top Decliners

Main Board

Symbol

Price

%Chg

Change